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Langerhans cell histiocytosis (LCH) is character-
ized by inflammatory lesions that include path-
ological langerin+ DCs. LCH has pleotropic 
clinical presentations ranging from single lesions 
cured by curettage to potentially fatal multi-
system disease. The first descriptions of LCH, 
including Hand-Schüller-Christian disease and 
Letter-Siwe disease, were based on anatomical 
location and extent of the lesions (Arceci, 1999). 
The diagnosis of high-risk LCH, defined by in-
volvement of “risk organs” which include BM, 
liver, and spleen, conferred mortality rates >20%, 
where patients with disease limited to non-risk 
organs (low-risk LCH) had nearly 100% survival, 
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Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by 
the accumulation of CD207+ dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-
V600E mutations have been reported in LCH. In this study, lesions from 100 patients were 
genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207+ DCs. 
BRAF-V600E expression in tissue DCs did not define specific clinical risk groups but was 
associated with increased risk of recurrence. Strikingly, we found that patients with active, 
high-risk LCH also carried BRAF-V600E in circulating CD11c+ and CD14+ fractions and in 
bone marrow (BM) CD34+ hematopoietic cell progenitors, whereas the mutation was re-
stricted to lesional CD207+ DC in low-risk LCH patients. Importantly, BRAF-V600E expression 
in DCs was sufficient to drive LCH-like disease in mice. Consistent with our findings in  
humans, expression of BRAF-V600E in BM DC progenitors recapitulated many features of  
the human high-risk LCH, whereas BRAF-V600E expression in differentiated DCs more closely 
resembled low-risk LCH. We therefore propose classification of LCH as a myeloid neoplasia 
and hypothesize that high-risk LCH arises from somatic mutation of a hematopoietic progeni-
tor, whereas low-risk disease arises from somatic mutation of tissue-restricted precursor DCs.
© 2014 Berres et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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The first recurrent somatic genetic mutation in LCH, 
BRAF-V600E, was recently reported in 57% of LCH lesions 
(Badalian-Very et al., 2010). Subsequently, recurrent BRAF-
V600E mutations were reported in LCH as well as the related 
disorder Erdheim-Chester disease (ECD; Sahm et al., 2012; 
Satoh et al., 2012; Haroche et al., 2013). Case reports of two 
other LCH patients describe a potential activating BRAF-
V600D somatic mutation and a novel germline BRAF muta-
tion (Satoh et al., 2012; Kansal et al., 2013).
In this study, we investigate the clinical significance of the 
BRAF-V600E molecular signature and identify cells carrying 
the mutation to further define the cellular origins of LCH. 
We found that the presence of BRAF-V600E in pathological 
DCs within LCH lesions was associated with higher risk of 
refractory or recurrent disease. Importantly, we found that 
BRAF-V600E expression in circulating cells was also associated 
with disease severity in patients. Moreover, we demonstrate 
that BRAF-V600E expression in DC precursors is sufficient 
to induce an LCH-like phenotype in mice with risk organ 
involvement, whereas BRAF-V600E expression in differen-
tiated DCs induces an attenuated phenotype. These results 
support a pivotal functional role of the mutation in LCH 
pathogenesis. We propose a model in which somatic mutation 
of BRAF-V600E in hematopoietic progenitors versus differ-
entiated hematopoietic cells defines clinical risk in LCH.
RESULTS
BRAF genotype in LCH patients: frequency  
and clinical correlations
LCH lesions (n = 130) from 100 patients with LCH were 
analyzed for the presence of the BRAF-V600E mutation 
(Table S1). Patients were identified retrospectively by availability 
regardless of the extent of disease burden (Gadner et al., 2008). 
Despite clinical heterogeneity, LCH lesions are generally in-
distinguishable by histology, which led to the notion that the 
spectrum of clinical manifestations represents a single disorder, 
histiocytosis X (Lichtenstein, 1953). The designation “Langer-
hans cell histiocytosis” was subsequently proposed with dis-
covery of cytoplasmic Birbeck granules in the pathological 
infiltrating DCs in histiocytosis X lesions, a feature shared by 
epidermal Langerhans cells (Nezelof et al., 1973). Birbeck gran-
ules are intracytoplasmic organelles whose role has remained 
poorly understood since their first identification in 1961 
(Birbeck et al., 1961). Recent data revealed that the formation 
of the Birbeck granules is a consequence of the antigen capture 
function of a C–type II lectin receptor called langerin, recently 
named CD207 (Valladeau et al., 2000; Kissenpfennig et al., 
2005; Verdijk et al., 2005). Langerin was initially described spe-
cifically on human and mouse epidermal Langerhans cells and 
subsequently found on histiocytosis X lesions, further sup-
porting the epidermal Langerhans cell origin of the disease 
(Chikwava and Jaffe, 2004).
However, recent discoveries question the model of LCH 
arising from transformed or pathologically activated epidermal 
Langerhans cells. The cell-specific gene expression signature in 
langerin+ DCs within LCH lesions has been shown to be more 
consistent with immature myeloid DC precursors than epider-
mal Langerhans cells (Allen et al., 2010). Furthermore, mouse 
studies demonstrate that langerin is more promiscuous than 
previously appreciated (Ginhoux et al., 2007). In addition to epi-
dermal Langerhans cells, langerin is also expressed on a subset 
of DC expressing the integrin CD103 in non-lymphoid tissues 
(Merad et al., 2008) and its expression is modulated by the 
tissue environment in which DCs reside (Chang et al., 2010).
Table 1. Clinical and demographic characteristics by BRAF-V600E status
Characteristic V600E WT P-value
Gender Number (%) Number (%)
 Female 23 (35.9) 17 (47.2) 0.27
 Male 41 (64.1) 19 (52.8)
Age
 <2 yr 21 (32.8) 10 (27.8) 0.69
 2–8 yr 28 (43.8) 19 (52.8)
 >8 yr 15 (23.4) 7 (19.4)
Clinical risk category
 Low 52 (81.3) 31 (86.1) 0.53
 High 12 (18.7) 5 (13.9)
Single/multifocal
 Single 27 (42.2) 18 (50.0) 0.45
 Multifocal 37 (57.8) 18 (50.0)
CNS risk lesions
 No 36 (56.3) 24 (66.7) 0.31
 Yes 28 (43.8) 12 (33.3)
Diabetes insipidus
 No 58 (90.6) 34 (94.4) 0.50
 Yes 6 (9.4) 2 (5.6)
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with significantly higher frequency of relapse and lower survival 
(Fig. 1, A and B). The BRAF-V600E mutation was associated 
with approximately twofold increased risk of relapse/recur-
rence (hazard ratio 2.17, 95% CI: 1.06–4.46). Although both 
BRAF-V600E and high-risk status were associated with in-
creased risk of recurrence, BRAF-V600E was not signifi-
cantly associated with high-risk disease (Table 1). Despite the 
increased risk of recurrence from BRAF-V600E, the muta-
tion was not associated with any difference in overall survival 
(Fig. 1, C and D).
BRAF genotype in LCH lesions
In every case where there were multiple lesions, either syn-
chronous or recurrent, from the same patient (n = 16 patients), 
the BRAF genotype remained fixed, consistent with acquisi-
tion of BRAF-V600E as an early event in LCH pathogenesis 
(Table S2). Concordance between cell-specific Sanger se-
quencing of cDNA and qPCR of whole lesion gDNA was 
observed in 47 out of 48 cases. In the single discordant case 
(Sanger, wild-type; qPCR, V600E), it is possible that de-
creased allelic expression or incomplete transcriptome cover-
age of cDNA amplified from RNA may result in occasional 
false-negative tests with cDNA sequencing. The percentage 
of BRAF-V600E cells in LCH lesions varied widely from 
of tissue biopsies and informed consent, and the cohort largely 
represents patients seen by the Texas Children’s Histiocytosis 
Program or collaborators—including Cook Children’s Medical 
Center—over the past decade. Clinical characteristics of the 
patients represent a range of age, extent of disease, and clinical 
risk categories. Median follow-up for data from time of diag-
nosis was 2.3 yr (range, 0–9.3 yr).
Genotyping was determined by high-sensitivity quantita-
tive PCR (qPCR) of whole-lesion genomic DNA (gDNA) 
and/or cell-specific Sanger sequencing of cDNA from puri-
fied langerin+ cells. Overall, 64% (64/100) of the LCH pa-
tients had lesions expressing the BRAF-V600E mutation. 
The clinical significance of the BRAF mutation was analyzed 
by comparing BRAF genotype with categorical clinical vari-
ables including gender, age, single lesion versus multifocal 
lesions, high-risk versus low-risk clinical assessment, CNS 
risk location (skull base and orbit lesion are associated with 
increased risk of LCH-associated neurodegeneration; Grois 
et al., 1994), and diabetes insipidus versus no diabetes insipi-
dus. Survival and recurrence/relapse categories were analyzed 
by Kaplan-Meier estimates. BRAF genotype did not correlate 
with gender, age, extent of lesions, clinical risk status, CNS 
risk, or development of diabetes insipidus (Table 1). High-risk 
clinical status, regardless of BRAF genotype, was associated 
Figure 1. Clinical status, BRAF genotype, and clinical outcomes. (A) Estimates for refractory or recurrent disease in the study population by disease risk 
(red: high-risk, blue: low-risk). (B) Estimates for survival based on disease risk (red: high-risk, blue: low-risk). (C) Estimates for refractory or recurrent disease by 
lesion BRAF genotype (red: wild-type, blue: BRAF-V600E). (D) Estimates for survival based on lesion BRAF genotype (blue: wild-type, red: BRAF-V600E).
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been reported previously (Stover et al., 2008), to our knowl-
edge this is the first case of BRAF-V600E associated with a 
histiocytic lesion including features of JXG. In another case 
(LCH-ECD100), a patient with a history of ECD had a new 
bone lesion with histology consistent with LCH (CD207+, 
CD1a+, and S100A+) with the BRAF-V600E genotype. The 
presence of BRAF-V600E allele in ECD and the observation 
of serial ECD and LCH lesions have been reported previously 
(Pineles et al., 2011, 2012; Haroche et al., 2013). In this series, 
BRAF-V600E was not identified in lesions from additional 
patients with ECD (n = 2), JXG (n = 7), or Rosai-Dorfman 
disease (RDD; n = 5). Additionally, BRAF-V600E was not 
identified in several biopsies from patients evaluated for pos-
sible LCH, with subsequent histology consistent with diagno-
ses other than histiocytic disorders (n = 17; Table S3).
BRAF genotype in circulating blood and BM  
in LCH patients: frequency and clinical correlations
From the 100 patients with known BRAF genotype, peripheral 
blood samples were collected from 77 patients with clinically 
detectable active disease: 67 patients at the time of diagnosis 
before chemotherapy and 10 patients at time of relapse before 
0.01–74.5% of lesion cells, with a median of 8.0% (Table S2 
and Fig. 2 A). The level of detection of commercially available 
deep sequencing–based diagnostic strategies requires 5% 
cells with the BRAF-V600E mutation (Verma et al., 2012). In 
this series, 42% (34/82) of the LCH lesion samples would fall 
below that threshold, suggesting that LCH will require more 
sensitive diagnostic approaches, as BRAF genotype becomes 
part of clinical risk stratification. In a subset of samples (n = 7), 
cDNA from CD3+ T cells purified from LCH lesions was 
analyzed along with purified langerin+ cells. Where 4/7 
langerin+ cDNA samples had detectable BRAF-V600E, 
only wild-type BRAF was identified in all of the matched le-
sion CD3+ cDNA.
This series included three patients with a biopsy reported 
with features with LCH, and also with a history of other his-
tiocytic disorders. In two cases, LCH-JXG-098 and LCH-
JXG-099, the patients had lesions with mixed populations 
of histiocytes described as LCH (CD207+, CD1a+, and S100A+) 
and juvenile xanthogranuloma (JXG; fascin+, Factor XIIIa+, 
CD207, and CD1a). BRAF-V600E was detectable in le-
sions from one of the two JXG/LCH hybrid patients (LCH-
JXG099). Although serial and hybrid JXG and LCH have 
Figure 2. Identification of cells with 
BRAF-V600E mutation in LCH lesions, 
circulating cells, and BM aspirates.  
(A) gDNA was isolated from biopsies of LCH 
lesions, and the percentage of cells with the 
BRAF-V600E allele was estimated by qPCR 
(line = median, 8.0%). (B) gDNA was isolated 
from PBMCs of patients with active LCH be-
fore initial therapy or at a time of recurrence 
before salvage chemotherapy. The percentage 
of circulating cells with the BRAF-V600E allele 
in patients from different clinical risk catego-
ries was estimated by qPCR. (C) Estimate of 
recurrence by circulating BRAF status among 
those who were clinically classified with low-
risk LCH (blue = no circulating cells with 
BRAF-V600E detected, red = circulating cells 
with BRAF-V600E detected). (D) gDNA was 
isolated from gradient-separated leukocytes 
from synchronous peripheral blood and BM 
aspirate collected from patients with active 
LCH. The percentage of cells with the BRAF-
V600E allele was determined by qPCR. (Every 
bar represents a single blood sample; techni-
cal duplicates were used in all experiments.) 
(E) The percentage of circulating cells with the 
BRAF-V600E allele was determined by qPCR 
of serial PBMC samples in one patient with 
disease refractory to multiple salvage thera-
pies (red), and finally cured with clofarabine 
(green). (Every data point represents a single 
blood sample; technical duplicates were used 
in all experiments.)
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peripheral lesions was documented as JXG. In most cases, 
percentage of BRAF-V600E cells in BM and peripheral blood 
were similar (Fig. 2 D).
Serial blood samples were analyzed from patients with 
circulating cells with BRAF-V600E identified at diagnosis 
or at an early episode of relapse/refractory disease. In 100% 
(14/14) of episodes where there was no clinical, imaging, or 
laboratory evidence of active LCH documented in the medi-
cal record, the peripheral blood had no detectable cells with 
BRAF-V600E. In 97% (29/30) of episodes of patients with 
clinically defined active LCH, BRAF-V600E was detected in 
peripheral blood cells. In patients with circulating BRAF-
V600E cells in peripheral blood at a time of active disease, 
analysis of circulating blood for BRAF-V600E defined active 
LCH with 97% sensitivity and 100% specificity (Table S4). In 
one case of a patient who developed symptoms of high-risk 
LCH at 6 mo of age (LCH075), BRAF-V600E cells were 
identified in multiple lesion samples and peripheral blood at 
the time of diagnosis; however, BRAF-V600E was not identi-
fied in a cord blood sample harvested at birth, suggesting 
that a precursor population was too rare to identify or that the 
somatic mutation was acquired at a later time (see Fig. 3 B  
and Fig. 4 B). These data demonstrate that the BRAF-V600E 
“bar code” may be used not only to diagnose high-risk LCH 
but also may potentially be tested in serial samples over time 
as a measure of residual disease (Fig. 2 E).
BRAF-V600E may be expressed in CD34+ hematopoietic 
stem and progenitor cells (HSPCs) in LCH patients
To identify the circulating cells harboring the BRAF-V600E 
mutation, peripheral blood and BM aspirate fractions were 
analyzed. Samples were selected from available aliquots of 
viably stored peripheral blood mononuclear cells and BM as-
pirates from samples with BRAF-V600E detected in unsorted 
blood and BM aspirate (Table 2). Peripheral blood was first 
sorted into CD14+ monocytes, HLA-DR+CD11c+ classical 
DCs, BDCA2+ plasmacytoid DCs, and CD3CD19CD56
CD14CD11c negative fraction (Fig. 3 A). gDNA was then 
amplified and tested for the presence of BRAF-V600E. In all 
cases where BRAF-V600E was identified in the whole pe-
ripheral blood sample, it was also detected in CD11c+ DCs 
salvage chemotherapy (Table S1). Circulating cells with BRAF-
V600E were identified in 17 of the patients (0.02–2.2% of 
peripheral blood mononuclear cells), all of whom had BRAF-
V600E identified in biopsy samples (Table S4 and Fig. 2 B). 
Clinical correlation with risk group shows that among pa-
tients with BRAF-V600E lesions, circulating BRAF-V600E 
was identified in 100% (12/12) of patients with high-risk dis-
ease (clinically documented liver, spleen, or BM involvement 
by LCH cells) and in 13% (5/39) of patients with low-risk 
disease. Circulating BRAF-V600E cells were not detected in 
peripheral blood gDNA from any of the patients with wild-
type BRAF lesion (0/26). The presence of BRAF-V600E in 
circulating cells in patients with active LCH with BRAF-
V600E lesions therefore correlates with 100% sensitivity and 
87% specificity for clinically defined high-risk disease. All of 
the clinical low-risk patients with circulating BRAF-V600E 
cells (n = 5) had multifocal lesions in more than one organ 
system (including skin, bone, gastrointestinal mucosa, and 
pituitary), and this group had significantly higher frequency 
of recurrent/refractory disease than clinical low-risk patients 
without circulating BRAF-V600E cells detected (hazard ratio 
3.31, 95% CI: 0.94–11.70; Fig. 2 C). Clinical risk categories 
were assigned according to the medical record. It is possible 
that these patients were incompletely evaluated or had sub-
clinical liver/spleen/BM involvement. For example, patient 
LCH068 had biopsy-proven skin and bone lesions, but splenic 
lesions noted on abdominal ultrasound were not biopsied 
and the patient was regarded as multi-system low-risk by the 
treating team. Circulating BRAF-V600E cells were identified 
in this patient in this study. Because the initial therapy is the 
same for low-risk and high-risk LCH patients, the risks of 
proving liver or spleen involvement in cases where imaging is 
equivocal may not be warranted. Interestingly, the described 
splenic lesions resolved after successful therapy. This example 
highlights the limitations of conventional staging strategies.
Similarly, BRAF-V600E was detected in BM aspirate 
from 100% (7/7) of patients with BRAF-V600E lesions with 
active high-risk LCH (Table S5). qPCR estimated 0.2–2.1% 
of BM cells in this series with BRAF-V600E mutation. Inter-
estingly, pathology reports describe abnormal findings in only 
43% (3/7) of these patients, and one with mixed phenotype 
Table 2. Analysis of BRAF-V600E in peripheral blood and BM aspirate populations
Sample BRAF 
lesion
Circulating  
BRAF
CD11c+ PB CD14+ PB BDCA2+ PB CD3+ PB CD19+ PB CD34+ BM CD14+ BM V600E in 
CFU assays
Cord  
blood
LCH009 V600E Yes + + 0 + +
LCH014 V600E Yes + + 0
LCH040 V600E Yes + + 0 0 0
LCH067 V600E Yes + + 0 0 + + + +
LCH068 V600E Yes + + + 0 + + + +
LCH070 V600E Yes + + 0 0 + + +
LCH075 V600E Yes + + 0 0 0 0 + 0
LCH077 V600E Yes + + 0 0 0
PB, peripheral blood; BM, BM aspirate.
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CD34+ cells, consistent with somatic mutation of the hema-
topoietic stem progenitor cell. Lineage CD34+ HSPCs iso-
lated from BM aspirate from two patients with high-risk 
LCH were used in CFU assays. The percentage of colonies 
with BRAF-V600E was similar to the percentage of CD34+ 
cells from BM aspirate carrying the mutation in both cases 
(Fig. 4 C). Due to the small number of cells, colonies were 
pooled to perform BRAF genotyping. BRAF-V600E colo-
nies were identified in the macrophage/monocyte colonies 
from the LCH068 sample. The colony sizes were smaller with 
insufficient DNA to perform BRAF genotyping on pheno-
type-specific colonies for LCH067 (unpublished data). Together, 
these data suggest that BRAF-V600E mutations may arise in 
hematopoietic stem cells and promote stem cell differentia-
tion into myelomonocytic precursor cells in patients with 
high-risk LCH.
Purified circulating CD3+ T lymphocytes and CD19+  
B lymphocytes were also analyzed for the expression of BRAF-
V600E in parallel aliquots from samples where BRAF-V600E 
was identified in peripheral monocyte/DC populations. BRAF 
was wild-type in CD3+ T cells from all samples. In the CD19+ 
fractions, BRAF-V600E was identified in some cases (LCH067, 
LCH068, and LCH070) but was absent from others (LCH040, 
LCH075, and LCH077). In all of the samples where BRAF-
V600E was identified in peripheral CD19+ B lymphocytes, the 
mutation was also identified in CD34+ HSPCs from BM aspi-
rate. In LCH075, BRAF-V600E was identified in neither 
CD34+ HSPC from BM aspirates nor circulating CD19+  
B lymphocytes (Table 2 and Fig. 4 D). These observations are 
consistent with the potential of hematopoietic progenitors 
with BRAF hyper-activation to develop into B cells as well as 
(0.2–25.2%) and CD14+ monocytes (0.07–5.4%). One case, 
LCH068, was initially categorized as low-risk multisystem by 
the treating team but with splenic lesions of uncertain etiol-
ogy as described above. This patient was found to have 1.2% 
circulating BRAF-V600E cells, developed aggressive disease, 
and ultimately required multiple rounds of salvage therapy. In 
this patient, BRAF-V600E was detected in BDCA2+ fraction 
(23.5%), in addition to CD11c+ (25.2%) and CD14+ (5.4%) 
fractions (Fig. 3 B). BRAF-V600E was undetectable in the 
negative fraction in all cases (unpublished data).
It remains possible that the circulating cells identified in 
this series could represent “leaking” lesion or tumor cells rather 
than LCH precursors. However, the statistically significant 
frequency in patients with high-risk LCH and failure to iden-
tify any circulating cells in patients with large single-lesion 
tumor burden favor a precursor versus a lesional origin of 
these cells. To further explore the possibility that circulating 
cells could represent leaking tumor cells, we performed FACS 
analysis on a series of blood samples with detectable circulat-
ing BRAF-V600E and consistently failed to identify circulat-
ing CD207+ cells above background (<0.01%; not depicted).
BM aspirate samples were also analyzed to determine the 
cellular origins of the BRAF-V600E mutation (Fig. 4 A). 
They were sorted into CD34+ HSPCs, differentiated CD14+ 
monocytes, and a negative fraction, which included myeloid 
and lymphoid precursors as well as CD14-negative leuko-
cytes (Fig. 4 B). In 4/5 BM aspirate samples from patients 
with BRAF-V600E cells in lesions and high-risk organ involve-
ment (including patient LCH068 who was clinically classified 
as low-risk but with undefined splenic lesions that resolved 
with therapy), the BRAF-V600E mutation was identified in 
Figure 3. BRAF-V600E localizes to circulating myeloid DCs and monocytes in peripheral blood. (A) Sorting strategy for peripheral blood mono-
nuclear cells into monocyte (CD14+), myeloid DC (lineage HLADR+ CD11c+ BDCA2+), and plasmacytoid DC (lineage HLADR+ BDCA2+) fractions. (B) Per-
centage of BRAF-V600E cells in circulating monocyte and DC fractions from the indicated LCH patients. (Every bar represents a single sorted blood 
sample; technical duplicates were used in all experiments.)
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progressively increased in size with age (Fig. 5 B, bottom), and 
by 20 wk of age, all mice analyzed also displayed small le-
sions in the lung (Fig. 5 B, top). Flow cytometry analysis re-
vealed an increased number of mainly MHC II+CD11c+ DCs 
(Fig. 5 C) in the liver of BRAF600Elangerin mice, whereas the 
number of DCs in the lung and total numbers of macro-
phages, NK cells, B cells, and T cells in the tissues were un-
affected (Fig. 5, C and D). Immunofluorescence (IF) staining 
further confirmed that a significant proportion of liver tis-
sue–infiltrating cells also expressed langerin (Fig. 5 E). Impor-
tantly, we failed to detect anemia or alteration of circulating 
blood DC numbers in 12- or 20-wk-old BRAFV600Elangerin 
mice (see Fig. 7, B and C).
Our results in patients showing that BRAF-V600E ex-
pression in early hematopoietic precursors in human patients 
correlate with high-risk LCH and early involvement of risk 
organs prompted us to assess whether BRAF-V600E expres-
sion at earlier stages of DC development can affect LCH pheno-
type. Thus, we generated another mouse model in which the 
BRAF-V600E conditional allele was expressed under 
the CD11c promoter. In mice, CD11c is expressed on com-
mitted DC progenitors and remains expressed throughout 
DC differentiation (Merad et al., 2013). In striking contrast 
to BRAFV600Elangerin mice, BRAFV600ECD11c mice rapidly 
monocytes and myeloid DCs. The absence of BRAF-V600E 
from T cells may be due to preferential commitment of the 
BRAF-V600E–expressing precursor to the myeloid and B cell 
lineages or to T cell–specific toxicity.
BRAF-V600E expression in the DC lineage  
drives formation of LCH-like lesions in mice
To determine if the BRAF-V600E expression identified in 
LCH lesions is not only a marker but also an essential driver 
of LCH pathogenesis, we generated a new mouse model in 
which we enforced the expression of conditional BRAF-V600E 
allele under the langerin promoter (BRAFV600Elangerin). In mice, 
langerin is absent from DC progenitors and is expressed only 
in differentiated tissue-resident DCs including epidermal 
Langerhans cells and a subset of tissue DCs that also express 
the integrin CD103 (Merad et al., 2008). Expression of 
BRAF-V600E in this mouse model remains under the con-
trol of the constitutive BRAF promoter similar to what oc-
curs in patients with a somatic BRAF mutation in exon 15 
(Badalian-Very et al., 2010). BRAFV600Elangerin mice were vi-
able and developed normally without gross phenotypical al-
terations compared with control littermates. However, by 12 wk 
of age, BRAFV600Elangerin mice developed small inflamma-
tory infiltrates restricted mainly to the liver (Fig. 5 A) that 
Figure 4. BRAF-V600E localizes to 
CD34+ hematopoietic progenitor cells in 
BM. (A) Sorting strategy for BM aspirate cells 
into HSPCs (CD34+) and monocytes (CD14+). 
(B) CD34+ and CD14+ cells were sorted from 
BM aspirate fractions, gDNA was purified and 
amplified, and then the BRAF-V600E allele 
was detected by qPCR. (C) Percentage of 
CD34+ cells with BRAF-V600E in BM aspirate 
and the percentage of BRAF-V600E cells ob-
tained from CD34+ HSPC-derived colonies 
generated in CFU Assay in two LCH patients. 
(D) PBMCs were sorted by FACS into CD3+ and 
CD19+ fractions. Percentage of peripheral B 
and T cells with BRAF-V600E in different LCH 
patients. (B–D: every bar represents a single 
sorted blood sample; technical duplicates 
were used in all experiments.)
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LCH lesions, mitoses were not observed in the granuloma-
tous lesions observed in BRAFV600ECD11c mice (Senechal 
et al., 2007; Fig. 6 B).
We confirmed that lesional MHC II+CD11c+ DCs isolated 
from the liver of BRAFV600ECD11c mice specifically expressed 
the BRAF-V600E mutation as assessed by mutation-specific 
qPCR (Fig. 7 A). Importantly, and consistent with the data in 
patients with high-risk multi-systemic LCH, BRAF-V600E 
was also present in BM-resident common DC progenitors 
(CDPs) in BRAFV600ECD11c mice (Fig. 7 A), whereas it was 
absent from BM progenitors in BRAFV600Elangerin mice (not 
depicted). The BRAF-V600E mutation was restricted to the 
DC lineage and was absent from early myeloid precursors or 
multipotent progenitors in BRAFV600ECD11c mice. Expres-
sion of the mutation in DC-restricted precursors was asso-
ciated with severe anemia, confirming BM involvement in 
these mice (Fig. 7 C), together with a dramatic expansion of 
developed an aggressive LCH-like disease phenotype with 
a penetrance of 100% associated with a decreased lifespan. 
Along with severe hepatosplenomegaly and lymphadenopa-
thy, organized histiocytic infiltrates were identified in the 
skin, liver, spleen, and lungs of all mice by 8 wk of age, resulting 
in a broad destruction of tissue architecture by 16 wk of age 
(Fig. 6, A–C). Histologically, the histiocytic lesions observed 
in BRAFV600ECD11c mice exhibited classical granulomatous 
organization, including multinucleated giant cell formation 
which is frequently observed in human LCH (da Costa et al., 
2005; Fig. 6 B). These lesions were associated with a massive 
increase of MHC II+CD11c+ DCs (Fig. 6 D) with a classical 
DC shape (Fig. 6 E, higher magnification). The vast majority 
of the CD11c+ cells accumulating in the tissues also expressed 
high levels of langerin protein (Fig. 6 E) associated with a 
dramatic increase of langerin mRNA transcripts in tissues 
compared with control littermates (Fig. 6 F). As in human 
Figure 5. BRAFV600Elangerin mice spontaneously developed progressive accumulation of inflammatory infiltrates in peripheral tissue.  
(A and B) BRAFV600Elangerin mice were generated as described in Materials and methods and sacrificed at 12 wk (A) or 20 wk (B). Representative lung  
and liver sections were stained by H&E (in total at least 4–5 mice per group were analyzed; arrows indicate inflammatory infiltrates; bars, 100 µm).  
(C and D) Lung and liver tissue of BRAFV600Elangerin mice and control littermates were harvested at 12 wk of age and single cells suspensions were ana-
lyzed by multicolor flow cytometry analysis after digestion with collagenase. Absolute numbers of total MHCII+ CD11c+ DCs, MHCII+ CD11c+ CD103+ DCs, 
and MHCII+ CD11c+ CD11b+ DCs are presented (C, all cells are pregated on singlets, viable CD45+ cells, n = 3 per group, representative of two independent 
experiments). Absolute number of tissue infiltrating total hematopoietic CD45+ cells, F4/80+ macrophages, total CD3+ NK1.1 T cells, total CD3+ NK1.1 
CD4+ CD8 T cells, total CD3+ NK1.1 CD4+ Foxp3+ T reg cells, total CD19+ B220+ B cells, and total CD3 NK1.1+ NK cells are depicted in D (all cells are 
pregated on singlets, viable CD45+ cells, n = 3 per group, representative of two independent experiments). (E) Representative picture of IF staining for 
langerin in liver lesion of 12-wk-old BRAFV600Elangerin mouse. Bars, 100 µm. Data are shown as mean ± SEM. *, P < 0.05.
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The granuloma lesions observed in BRAFV600ECD11c 
mice contained, in addition to massive CD11c+ langerin+ 
infiltrates, a large number of macrophages, NK cells, B cells, 
and T cells, with a specific accumulation of regulatory 
blood circulating DC precursors (pre-DCs) and blood cir-
culating DCs (Fig. 7 B), whereas blood pre-DCs and DC 
numbers, as well as hemoglobin levels, remained unaffected 
in BRAFV600Elangerin mice.
Figure 6. BRAFV600ECD11c mice develop an aggravated phenotype with massive infiltration of MHCII+ CD11c+ langerin-expressing cells in pe-
ripheral tissues. (A) Representative pictures of the spleen and liver of BRAFV600ECD11c mice (right) and control littermates (left) at 12 wk of age (n = 16 per 
group). (B) Representative H&E staining of liver and lung tissue sections of BRAFV600ECD11c mice and corresponding controls at the indicated ages (arrow 
marks multinucleated giant cells; bars, 100 µm; n = 5–11 animals per group). (C) H&E staining of back skin tissue sections of 12-wk-old BRAFV600ECD11c mice 
and controls (arrows indicate multinucleated giant cells; bars, 100 µm; n = 4 per group). (D) Absolute numbers and percentages of MHC II+ CD11c+ DC among 
total CD45+ lung and liver cells in 12-wk-old BRAFV600ECD11c mice and control littermates were determined by multicolor flow cytometry (all cells pregated 
on singlets, viable cells, n = 3–5 per group, representative of three independent experiments). (E) Representative image of frozen liver tissue section isolated 
from the liver of 16-wk-old BRAFV600ECD11c mice stained with anti-langerin mAb (left) and anti-CD11c mAb (right) or with both langerin and CD11c mAb 
(merged) and analyzed by confocal microscopy (bars, 100 µm). (F) Langerin mRNA expression in whole liver tissue of BRAFV600ECD11c mice and corresponding controls 
was analyzed by qPCR (normalized to Gapdh mRNA expression, n = 6–11 per group). All data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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DISCUSSION
The etiology of LCH has intrigued and eluded the medical 
community for the past century as a paradox of a collection 
of highly variable clinical manifestations connected by com-
mon histopathology. The resulting debate on LCH patho-
genesis has recently focused on aberrant activation versus 
malignant transformation of the epidermal Langerhans cell. 
Previous studies demonstrated that pathological DCs in LCH 
are clonal (Willman et al., 1994; Yu et al., 1994) and that the 
BRAF-V600E point mutation occurs with significant fre-
quency in LCH lesions (Badalian-Very et al., 2010; Haroche 
et al., 2012; Sahm et al., 2012; Satoh et al., 2012). In this study, 
T cells (Fig. 7, D and E) closely resembling LCH lesions in 
humans (Hicks and Flaitz, 2005; Senechal et al., 2007). Im-
portantly, these granuloma-like lesions were also associated 
with a significant increase in several chemokines and cyto-
kines (Ccl2, Ccl5, Il-6, Il-10, IFN-, and TGF-; Fig. 7 F), 
consistent with the “local cytokine storm” that character-
izes human LCH (Allen et al., 2010). Additionally, a local 
fibrotic response occasionally observed in human LCH gran-
uloma and likely due to high cytokines expression—for ex-
ample, TGF- and IFN- (de Graaf et al., 1996)—was 
detected within the granulomas and the surrounding stroma 
(not depicted).
Figure 7. Expression of BRAF-V600E in early BM-resident DC progenitors in BRAFV600ECD11c mice results in multi-systemic high-risk dis-
ease and is associated with high local cytokine expression and the recruitment of additional inflammatory cells. (A) Relative mRNA expression 
of BRAF-V600E in sorted BM lineage negative sca1+ c-kit+ (LSK), lin sca1 c-kit+ CD34+ CD16/32+ granulocyte myeloid progenitors (GMPs), lin sca1 
CD135+ c-kithigh CD115+ monocyte and DC progenitors (MDPs), and lin sca1 CD135+ c-kitlow CD115+ common DC progenitors (CDPs) and lung/liver 
CD45+ MHCII+ CD11c+ DCs in BRAFV600ECD11c mice as assessed by mutation-specific qPCR (data normalized to total BRAF expression, no BRAF-V600E 
expression detected in corresponding cells of control mice, n = 3, pooled data of three independent isolations). (B and C) Relative numbers of viable sin-
glet CD11b+ CD115+ Flt3+ pre-DCs and CD11c+ MHCII+ DCs among circulating viable, singlet CD45+ cells (B) and hemoglobin levels (C) in BRAFV600ECD11c 
mice, BRAFV600Elangerin mice, and control mice (n = 4–10 per group, pooled data of four independent experiments, each data point represents one mouse). 
(D) Immunohistochemical analysis of liver and lung tissue sections stained with indicated mAb in BRAFV600ECD11c mice (top) and control littermates (bot-
tom; bars, 50 µm). (E) Absolute numbers of tissue-infiltrating total hematopoietic CD45+ cells, F4/80+ macrophages, total CD3+ NK1.1 T cells, total CD3+ 
NK1.1 CD4+ CD8 T cells, total CD3+ NK1.1 CD4+Foxp3+ T reg cells, total CD19+ B220+ B cells, total CD3 NK1.1+ NK cells, and total SiglecF+ CD11c 
eosinophils in lung and liver of BRAFV600ECD11c mice and control littermates as assessed by multicolor flow cytometry (n = 4–5 per group, representative 
of two independent experiments). (F) Local expression of indicated chemokines and cytokines in peripheral liver tissue was assessed by qPCR (data nor-
malized to Gapdh expression, n = 4–5 per group). All data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
JEM Vol. 211, No. 4 
Article
679
clinical risk groups. However, LCH lesions may represent 
only a superficial downstream manifestation of pathogenesis. 
If BRAF-V600E is the activating event, somatic mutation in 
a hematopoietic stem cell or myeloid DC restricted precur-
sors may determine progression to high-risk disease, potentially 
with lesions in BM, liver, spleen, or virtually any organ system. 
Neoplastic transformation of an early multipotent myeloid 
precursor could explain the occurrence of coexistent histio-
cytic disorders (JXG/LCH and ECD/LCH) in the same pa-
tients in this study, as well as in others, and the common 
BRAF-V600E mutation in both LCH and ECD (Stover et al., 
2008; Pineles et al., 2011; Haroche et al., 2012). Moreover, 
immature myeloid origins of high-risk LCH are consistent 
with effectiveness of acute myelogenous leukemia–based sal-
vage chemotherapy with cytarabine/cladribine and clofara-
bine for patients with recurrent/refractory high-risk LCH 
(Bernard et al., 2005; Rodriguez-Galindo et al., 2008).
We further hypothesize that if the initiating mutation 
occurs in tissue-restricted DC progenitors, multifocal low-
risk disease could result. Finally, if an initiating mutation arises 
in a differentiated DC with restricted tissue tropism, low-risk 
LCH with a single lesion could result. In this model, as patho-
logical DCs from circulating or tissue-restricted precursors 
migrate to sites of lesion formation, they may acquire CD1a 
and langerin expression and recruit and activate “innocent 
bystander” inflammatory cells, including macrophages and 
lymphocytes, resulting in the formation of characteristic 
granulomatous LCH lesions mediated, at least in part, by an al-
tered expression of chemotactic cytokines. Based on the mis-
guided differentiation of the pathological DC and their ability 
to recruit and activate additional inflammatory cells, we propose 
that the answer to the neoplasia versus inflammation debate is 
that both processes may be essential to LCH pathogenesis.
The results from this study also revealed some innovative 
diagnostic tools that will need to be validated in future pro-
spective clinical studies. The qPCR assay was highly sensitive 
and specific for diagnosis of LCH. In the absence of fresh tis-
sue on which to perform cell sorting, qPCR on whole tissue 
samples appears to be a robust strategy compared with se-
quencing strategies for unmanipulated biopsy samples, many 
of which have pathological DC content <5%. The BRAF-
V600E mutation is clinically relevant, as LCH patients with 
BRAF-V600E expression within the lesions were approxi-
mately twice as likely to have recurrent or refractory disease 
as patients with wild-type lesions, and detection of BRAF-
V600E in peripheral blood was 100% sensitive for clinical 
high-risk disease associated with significant mortality. Pa-
tients with clinical low-risk multisystem LCH but evidence of 
circulating BRAF-V600E–expressing cells also had a signifi-
cantly higher chance of recurrent/refractory disease compared 
with low-risk multisystem LCH patients without detectable 
circulating BRAF-V600E cells. It is possible that our findings 
differ with previous reports of absent circulating BRAF-
V600E cells due to the relative insensitivity of deep sequenc-
ing and/or lack of inclusion of patients with BRAF-V600E 
and active high-risk disease in the study cohorts (Sahm et al., 
we demonstrate that BRAF status of pathological DCs in 
LCH lesions is fixed in synchronous lesions as well as serial 
relapse samples, consistent with the BRAF-V600E mutation 
as an early or initiating event in LCH pathogenesis, tipping 
the scales to classify LCH as a neoplastic disorder. We also 
demonstrate that BRAF-V600E mutation in patients with 
high-risk LCH is a somatic event that seems to arise in very 
early myelomonocytic precursors or in stem cells that may 
be subsequently driven to myelomonocytic differentiation, 
whereas BRAF-V600E mutation in patients with low-risk 
LCH was not routinely identified in circulating cells, suggest-
ing it may be restricted to differentiated tissue-resident DCs 
in these patients. We cannot entirely exclude that the BRAF-
V600E–expressing cells in the blood and BM of high-risk 
patients might represent circulating lesional cells; however, 
the statistically significant presence of circulating cells in high-
risk patients and infrequent detection in low-risk patients, 
lack of langerin+ cells in the blood of patients with circulating 
BRAF-V600E–expressing cells, and the identification of the 
mutation in the CD34+ fraction in the BM render this hy-
pothesis unlikely. CD34 is a major positive marker of human 
HSPCs and is not expressed by mature blood cells or tissue-
restricted myeloid cells (Kondo et al., 2003). Furthermore, 
the progenitor nature of BRAF-V600E–expressing CD34+ 
cells is greatly supported by the CFU assay performed with 
sorted CD34+ BM cells of two high-risk patients, which yield 
a percentage of colonies with BRAF-V600E similar to the 
percentage of CD34+ cells from BM aspirates. This shows the 
high proliferative potential of mutation-bearing CD34+ BM 
cells, defining them as colony-forming cells/progenitor cells. 
As lesional cells display only low proliferation rate (Senechal 
et al., 2007), contamination of the assay with circulating LCH 
cells seems implausible.
Using two novel mouse models, we established that the 
BRAF-V600E mutation in myeloid cells results in the forma-
tion of LCH-like lesions in mice. Induction of physiological 
expression levels of BRAF-V600E in BM DC progenitors 
induced a severe LCH-like phenotype with multi-organ 
involvement and reduced lifespan, whereas expression of 
BRAF-V600E in differentiated DCs resulted in an attenuated 
phenotype. Consistent with identification of BRAF-V600E 
mutation in patients with high-risk LCH, BRAF-V600E  
expression in hematopoietic progenitors in mice resulted in 
BM involvement, indicated by severe anemia and expansion 
of circulating DC precursors and circulating DC, whereas 
anemia or alteration in circulating DCs was not detectable 
when the mutation was restricted to the more differentiated 
DCs. These findings implicate the BRAF-V600E mutation as 
a driver of LCH-like disease in mice. Although these mouse 
models recapitulate several features of human LCH, the ex-
tent to which these results can be translated to human LCH 
pathology remains a matter for investigation.
Based on our results, we propose a new hypothetical 
model of LCH in which the initiating cell defines the extent 
of the disease. The mixed inflammatory lesion that defines 
LCH clinically is indistinguishable between different LCH 
680 LCH: neoplasia arising from myeloid precursors | Berres et al.
LCH may arise through expression of BRAF-V600E in pre-
cursor cells and DCs but may also represent a valuable tool 
with which to develop and evaluate future therapeutic strate-
gies. In summary, the observation of BRAF-V600E in BM 
progenitor cells and immature circulating cells in patients 
with high-risk LCH, coupled with the development of LCH-
like lesions in mice expressing the BRAF mutation within 
the myeloid lineage, supports a causative role of BRAF-V600E 
in LCH pathogenesis and progression, consistent with classi-
fication of LCH as a bone fide myeloid neoplasia.
MATERIALS AND METHODS
Human studies
Subjects. LCH diagnosis was established by the presence of CD1a+ or 
CD207+ histiocytes in clinical biopsy specimens along with characteristic his-
topathology. Clinical data were collected from approved chart reviews. Stud-
ies with patient tissue and clinical data were performed according to protocols 
approved by the Institutional Review Board of Baylor College of Medicine.
Analysis of clinical variables. Frequency distributions of demographic 
and clinical characteristics were tabulated for those with and without the 
BRAF-V600E mutation. The crude odds ratio (OR) and 95% confidence 
interval (CI) were estimated using unconditional logistic regression for the 
association between each characteristic and mutation status. Kaplan-Meier 
survival estimates were calculated for recurrence/relapse and overall mortality. 
The sensitivity and specificity of circulating cells with BRAF-V600E were 
compared with the clinical assessment of disease risk (i.e., gold standard). 
All statistical analyses were performed using Intercooled Stata (version 12.1; 
StatCorp LP).
BRAF-V600E assays: LCH lesions. gDNA was isolated from frozen 
whole lesions, or from frozen sections cut from biopsies embedded in OCT 
blocks using the QIAamp DNA mini and QIAamp DNA micro protocols 
(QIAGEN), including treatment with RNase A (QIAGEN). When gDNA 
isolated from scrolls of formalin fixed and paraffin embedded (FFPE) ar-
chived biopsy samples were used, the samples were processed with QIAamp 
DNA FFPE Tissue kit per manufacturer’s protocol (QIAGEN), including 
treatment with RNase A. Purified gDNA (30 ng/sample) was used in the 
BRAF-V600E qPCR mutation assay (Somatic Mutation Assay for BRAF_476; 
QIAGEN). BRAF mutation and reference primers were included in each 
reaction. Duplicate reactions were performed for each sample. All experi-
ments were performed on an iQ5 iCycler (Bio-Rad Laboratories). The 
means of Ctmut and Ctref were calculated to determine Ct = Ctmut(ave)  
Ctref(ave). The CT was compared with a standard curve to estimate the per-
centage of cells with BRAF-V600E alleles. The standard curve was created by 
making 13 dilutions of gDNA from A375 cell line (American Type Culture 
Collection), which carries one allele of BRAF-V600E and one allele with 
wild-type BRAF per cell, with gDNA from HEK293 cell line (American 
Type Culture Collection), which carries two wild-type BRAF alleles per cell. 
The CT was plotted against the percentage of cells from A375/HEK293 
cell pools (0.1–100% BRAF-V600E) from which the gDNA was isolated. 
For each LCH gDNA sample, the percentage of cells with the BRAF-V600E 
mutation was then calculated based on the standard curve. Independent con-
trols (wild type and 100% BRAF-V600E cell lines) were routinely tested 
along with standard curve and experimental samples.
Cell-specific mutation analysis was performed in langerin+ and CD3+ 
cells purified from viable LCH lesions. Cell sorting, RNA purification, and 
cDNA amplification was performed as described previously (Allen et al., 
2010). BRAF sequence was analyzed in cDNA from purified cells by PCR 
amplification, followed by Sanger sequencing. BRAF-V600E was identified 
in cases where GAG peak was visible, along with wild-type GTG at codon 
600. Primers: forward, 5-AGCTCAATAGAGGCGAGAAT-3; reverse, 
5-AGCTCAATAGAGGCGAGAAT-3.
2012; Satoh et al., 2012). Future multi-center prospective 
studies will determine if multifocal clinical low-risk disease 
with circulating BRAF-V600E cells represents an indepen-
dent clinical risk category or simply reflects the limitation of 
existing clinical scoring strategies to accurately categorize 
low-risk versus high-risk disease.
In addition to potential clinical utility in risk stratification, 
BRAF mutation status might also be useful for disease sur-
veillance. In patients with circulating BRAF-V600E cells, 
detection of BRAF-V600E in peripheral blood was 97% sen-
sitive to active disease. The potential value of surveillance 
strategies in LCH is indicated by the published very high 
rates of treatment failure or disease reactivation, which may 
represent persistence of LCH precursor cells. In the Histiocyte 
Society trial LCH-I, 57–65% of high-risk patients were either 
nonresponders or had progressive disease at the sixth week of 
treatment with vinblastine or etoposide, and reactivations 
were observed in 55–61% (Gadner et al., 2001). The LCH-II 
study reported similar results with 51–64% nonresponse or 
progressive disease in high-risk patients treated with predni-
sone and vinblastine ± etoposide, and reactivations occurred 
in 46% of patients (Gadner et al., 2008). In this study, we ob-
served refractory or recurrent LCH in nearly 90% of our 
high-risk patients, with twofold increased risk across all risk 
groups in patients with the BRAF-V600E mutation. We ques-
tion the wisdom of generally treating clinical high-risk, or even 
clinical low-risk patients, with BRAF-V600E lesions initially 
with vinblastine, prednisone, or etoposide with such high 
rates of failure. As we are now able to identify BRAF-V600E 
minimal residual disease, future clinical trials will test sus-
tained responses to experimental therapies more efficiently.
In light of the findings of this study, we hypothesize that 
optimal therapy for LCH would specifically impact immature 
myeloid DC precursors. Targeted inhibition of BRAF-V600E 
is an obvious strategy with reported short-term responses in a 
pilot study of adults with features of LCH along with ECD 
(Haroche et al., 2013). Although potentially promising, the 
long-term efficacy of targeted therapy against BRAF in LCH 
remains to be proven. Even if effective, the relative mortality 
in most patients with LCH and the known toxicities of BRAF 
inhibition make optimal use of these agents an uncertain 
equation, especially in children where the effects of BRAF 
inhibition on development are unknown (Chapman et al., 
2011). In addition to chemotherapy or BRAF inhibition, 
novel strategies could include inhibition of myeloid growth 
factors, inhibition of maturation or migration of pathological 
DCs, and disruption of cell–cell interactions that recruit and 
activate bystander inflammatory cells.
Until now, development and evaluation of novel therapies 
for patients have been limited by a lack of animal models of 
LCH. Although enforcement of BRAF-V600E expression 
across a DC lineage in mice is not completely parallel to de-
velopment of somatic mutation in a single progenitor cell in 
humans, the BRAFV600ECD11c mouse is a promising model 
with significant similarity to high-risk human LCH. This 
model not only supports a model of pathogenesis in which 
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All animals were housed under specific pathogen-free (SPF) conditions and 
sacrificed at the indicated time points. All experiments were controlled using 
littermates negative for the cre recombinase transgene construct.
Histology, immunohistochemistry (IHC), and IF analysis. Langerin 
and CD11c staining was performed on acetone-fixed frozen tissues, and all 
other staining was performed on FFPE tissue at the Histology Shared Re-
source Facility of Mount Sinai School of Medicine and at the Baylor College 
of Medicine Pathology Core according to standard operating procedures. For 
IF staining with anti-langerin and CD11c mAb, fresh tissue was cryopre-
served in OCT (Sakura) and stored at 80°C. 8-µm-thick sections were air 
dried for 1 h and fixed in acetone for 20 min at 20°C. After incubation 
with 10% goat serum for 1 h, sections were stained overnight at 4°C with 
rat anti-langerin (clone eBioL31; eBioscience) or Armenian hamster anti-
CD11c (clone N418; eBioscience) mAbs. After several washing steps, sections 
were incubated for 60 min with goat anti–rat antibody labeled with Alexa 
Fluor 488 (Invitrogen) and goat anti–Armenian hamster labeled with Alexa 
Fluor 594 (BioLegend) and embedded in ProLong Gold Antifade Reagent 
with DAPI (Life Technologies). Images were acquired with a confocal micro-
scope (SP5 DM; Leica) and analyzed with ImageJ software (National Insti-
tutes of Health).
For the IHC analysis, 4-µm tissue sections were deparaffinized and rehy-
drated through xylene/absolute alcohol. Endogenous peroxidase activity was 
blocked by incubating the sections in methanol with 0.6% hydrogen perox-
ide for 10 min at room temperature. Heat-induced antigen retrieval was per-
formed with citrate buffer, pH 6.0 (Diagnostic BioSystems), in a steamer for 
15 min. To block nonspecific staining, Rodent Block M (Biocare Medical) 
was incubated with the section for 1 h at room temperature. Sections were 
stained with anti-CD3 (Abcam), anti–MHC II (BD), anti-FOXP3 (Bio-
Legend), or anti-CD68 (Thermo Fisher Scientific) mAbs overnight at 4°C. 
Application of the primary antibodies was followed by a 30-min incubation 
with a Rabbit on Rodent/Mouse on mouse/rat on Rodent Polymer-HRP 
(BioCare Medical) and visualized with DAB (Diagnostics BioSystems) as a 
chromogen with CAT hematoxylin counterstaining (BioCare Medical).
Flow cytometry analysis. Single cell suspension was obtained from indi-
cated tissues after digestion with 0.4 mg/ml of type IV collagenase (Sigma-
Aldrich) at 37°C for 45 min. For liver tissues, nonparenchymal cells were 
enriched by density gradient centrifugation with 40/70 Percoll (GE Health-
care) for 30 min at 1,100 rcf. BM and blood single cell suspensions were in-
cubated with RBC lysis buffer (BioLegend) for 2 min at room temperature 
before staining. mAbs specific to mouse CD45 (clone 30F11; BioLegend), 
MHC II (I-A/I-E; clone M5/114.15.2; BioLegend), CD11c (clone N418; 
eBioscience), CD103 (clone 2E7; eBioscience), CD11b (clone M1/70; Bio-
Legend), F4/80 (clone CI: A3-1; BioLegend), CD3 (clone 145-2C11; Bio-
Legend), CD4 (clone L3T4; BioLegend), NK1.1 (clone PK136; eBioscience), 
FoxP3 (clone FJK-16s; eBioscience), Sca-1 (clone D7; eBioscience), c-kit 
(clone 2B8; eBioscience), CD16/32 (clone 2.4G2; BD), CD135 (clone 
A2F10; eBioscience), CD115 (clone AFS98; eBioscience), CD34 (clone 
RAM34; eBioscience), and Siglec F (clone E50-2440; BD) were purchased 
from the indicated vendors. For intracellular FoxP3 staining, cells were fixed 
overnight in Fixation/Permeabilization buffer (eBioscience). Before acquisi-
tion, cells were resuspended in PBS/BSA 0.5%/EDTA (2 mM) solution with 
1 µg/ml of DAPI to exclude dead cells. For FoxP3 staining, cells were stained 
with live/dead fixable dead cell stain kit (Invitrogen) before fixation to assess 
viability. Multiparameter analysis was performed on the LSR II (BD) and an-
alyzed with FlowJo software.
qPCR. Total RNA was isolated from tissue using TRIzol reagent 
(Invitrogen) and transcribed with RNA to the cDNA EcoDry kit 
(Takara Bio Inc.). qPCR was performed and analyzed on a CFX384 
Touch Real-Time PCR Detection System (Bio-Rad Laboratories) using 
SYBR Green PCR Master Mix (Invitrogen) and the following prim-
ers: IFN- forward, 5-TCAAGTGGCATAGATGTGGAAGAA-3, 
and reverse, 5-TGGCTCTGCAGGATTTTCATG-3; IL-10 forward, 
BRAF-V600E assays: peripheral blood and BM aspirate. Buffy coat 
from fresh peripheral blood, BM aspirate, and cord blood samples was puri-
fied by spinning an equal volume over Histopaque-1077 (Sigma-Aldrich) at 
400 g for 30 min. Samples were washed with PBS, and then viably stored 
long-term in Recovery Cell Culture Freezing Media (Gibco) until they were 
thawed for gDNA isolation, per protocol described above, or used for sorting 
experiments. gDNA from sorted cells was purified with the QIAamp DNA 
Micro kit (QIAGEN), and then amplified with the REPLI-g Midi kit 
(QIAGEN) per manufacturer’s instructions. qPCR was performed as described 
above on the amplified gDNA. BRAF-V600E:wild-type standard curves were 
created for amplified gDNA from 13 dilutions of amplified gDNA from 
A375 cells with amplified gDNA from HEK293 cells.
BRAF-V600E assays: sorting peripheral blood. Purified leukocytes 
from peripheral whole blood were subjected to staining using anti–CD11c-
PE, anti–HLADR-APC-Cy7, lineage antibodies (anti-CD3–Pacific blue, 
anti-CD19–Pacific blue, and anti-CD56–Pacific blue), anti–CD14-APC 
(BD), and anti–BDCA2-FITC (Miltenyi Biotec). Thawed samples were 
blocked for 30 min in FcR-block (Miltenyi Biotec) and stained for 30 min 
in ice-cold PBS supplemented with 2 mM EDTA and 5% BSA. For purified 
peripheral blood populations, isolation of linHLADR+CD14CD11c+, 
linHLADR+CD14+, linHLADR+BDCA2+, and linHLADR+ precursor 
cells were achieved by six-color sorting on an Aria BSL2 (BD). B and T cell 
populations were isolated from select samples using anti–CD3-FITC and 
anti–CD19-PE (BD) on a MoFlo sorter (Beckman Coulter). Purified popu-
lations were sorted directly into ice-cold fetal bovine serum (Invitrogen), and 
gDNA was isolated using the QIAamp DNA Micro kit with RNase A treat-
ment and amplified with the REPLI-g Midi kit.
BRAF-V600E assays: sorting BM and cord blood. Purified cord blood 
and BM leukocyte populations were isolated by staining with anti–CD34-PE 
and anti–CD14-APC antibodies (BD) and subsequent three-color sorting 
for the CD34+CD14, CD34CD14+, and double-negative populations. Pop-
ulations were sorted into ice-cold fetal bovine serum (Invitrogen) and gDNA 
isolated using the QIAamp DNA Micro kit with RNase A treatment to re-
move endogenous RNA. All flow cytometry analysis was performed using 
FlowJo software (Tree Star).
BM CFU assays. Frozen healthy or patient BM samples were stained with 
anti-CD123–Brilliant violet 421, anti–CD38-FITC, anti–CD90-PE, anti-
lineage markers (CD3, CD4, CD8, CD11b, CD14, and GPA)–Tricolor, 
anti–CD34-PE-Cy7, anti–CD127-biotin, and anti–CD45RA-APC-Cy7 
antibodies (BioLegend, BD, or Invitrogen). Subsequently, biotin was de-
tected by streptavidin-APC (eBioscience). CD34+lin cells were sorted into 
methylcellulose (H4230; STEMCELL Technologies) containing 20 ng/ml 
IL-3, 10 ng/ml IL-6, 10 ng/ml IL-11, 10 ng/ml SCF, 50 ng/ml TPO, 
4 U/ml EPO, 50 ng/ml GM-CSF, and 10 ng/ml Flt3L (PeproTech), and 
cultured for 12–15 d, followed by colony classification and isolation of 
gDNA from single colonies with the QIAamp DNA Micro kit.
Mouse studies
Mouse models. All animal experiments performed in this study were ap-
proved by the Institutional Animal Care and Use Committee (IACUC) of 
Mount Sinai School of Medicine. BRAFV600Elangerin mice were generated 
by crossing mice expressing cre recombinase under the control of the murine 
langerin promoter (C57BL/6 background; provided by B. Claussen, Eras-
mus University Medical Center, Rotterdam, Amsterdam; Zahner et al., 
2011) with heterozygous mice carrying a cre-activated allele of BRAF-
V600E (BRAFV600Eca/wt, C57BL/6 background) in which wild-type 
BRAF is expressed in both alleles in the absence of cre-mediated recombina-
tion (provided by M.W. Bosenberg, Yale University, New Haven, CT; 
Dankort et al., 2007). BRAFV600ECD11c mice were created by crossing 
BRAFV600Eca/wt mice with mice expressing cre recombinase under the con-
trol of the CD11c promoter (C57BL/6 background; The Jackson Laboratory). 
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